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Study	Synopsis	
	
Background	 –	 The	 usually	 employed	 methods	 for	 non-invasive	 cardiovascular	 imaging	 using	
Magnetic	Resonance	 Imaging	 (MRI)	or	Computed	Tomography	 (CT)	 carry	potential	 risks	 for	kidney	
disease	 patients.	 An	 alternative	 contrast	 agent	 is	 needed	 to	 optimise	 imaging	 results	 while	
minimising	risks	in	this	vulnerable	patient	group.	Ferumoxytol	originally	developed	as	a	MRI	contrast	
agent	 and	 is	 currently	 licensed	 in	 the	 USA	 and	 Canada	 for	 iron-replacement	 therapy	 primarily	 in	
patients	 with	 kidney	 disease,	 still	 has	 excellent	 potential	 as	 MRI	 contrast	 agent	 in	 assessing	 the	
heart,	central	and	peripheral	vessels.	
	
Objectives	 -	 To	 determine	 the	 quality	 and	 clinical	 yield	 of	 Ferumoxytol-enhanced	 Magnetic	
Resonance	 Angiography	 (FeMRA)	 use	 in	 cardiovascular	 assessment	 of	 patients	 with	 late-stage	
chronic	kidney	disease	(CKD)	compared	with	current	standard-of-care	imaging	techniques.	
	
Study	Design	-	Single	centre	comparative	prospective	cohort	study.	
	
Setting	 and	 Participants	 -	 Patients	 with	 late-stage	 kidney	 disease	 undergoing	 conventional	
cardiovascular	 imaging	 as	 part	 of	 pre-operative	 kidney	 transplant	 candidacy	 assessment	 and	
haemodialysis	vascular	access	creation	or	surveillance	will	be	enrolled	from	the	Glasgow	Renal	and	
Transplant	Unit	and	followed	up	for	up	to	2	years.	
	
Interventions	 –	 Cardiovascular	 magnetic	 resonance	 angiography	 using	 3mg/kg	 body	 weight	 of	
Ferumoxytol	as	intravenous	contrast	agent	for	enhancement	as	part	of	cardiovascular	assessment.	
	
Main	Outcome	Measures	–	Head-to-head	comparisons	of	imaging	quality	and	diagnostic	accuracy	of	
FeMRA	compared	with	standard	imaging	techniques.	
	
Limitations	-	Single	centre	design.	The	separation	of	investigations	in	time	will	allow	certain	findings	
to	evolve	and	become	more	or	less	apparent.	
	
Conclusions	-	The	FeMRA	in	CKD	Study	will	be	of	sufficient	size	and	scope	to	1)	evaluate	the	quality	
and	 diagnostic	 utility	 of	 FeMRA	 in	 late-stage	 CKD,	 and	 2)	 establish	 the	most	 appropriate	 imaging	
modality	for	cardiovascular	assessment	in	patients	with	late-stage	CKD.	
	9	
	
Study	flow	chart	
 
 
 
Group A. Pre-kidney 
transplant assessment 
	
	
Invited to participate: 
• Meet inclusion criteria 
Informed consent (Form A) 
Analysis 
Primary Outcome 
• Comparison of FeMRA with standard imaging techniques in 
imaging quality and diagnostic accuracy in assessment of vascular 
anatomy (all cohorts) 
• Change in cardiac anatomical and functional parameters after 
AVF/AVG creation (CMR cohort) 
Enrolment 
Excluded: 
• Did not meet 
inclusion criteria 
Excluded: 
• Declined to 
participate 
Recruitment via renal databases at 
NHS Greater Glasgow and Clyde, 
eligibility screening 
 
	
Group B. Vascular mapping 
before AVF/AVG creation 
	
	Standard care: 
- CTA abdominal and 
aortoiliac vasculature before 
transplant listing 
Study Visit: 
1st   FeMRA abdominal and 
aortoiliac vasculature & CMR 
Study Visits: 
1st   FeMRA vascular mapping before 
AVF/AVG creation & baseline CMR 
2nd   FeMRA & CMR 6 weeks post-
AVF/AVG creation	
Informed consent (Form B) 
Standard care: 
- US vascular mapping before 
AVF/AVG creation 
 
- 6 week US graft arm 
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Study	visits	chart
Pre-transplant 
assessment 
Visit 2 
6-12 weeks 
Patient recruited to study. 
Informed consent (Form B) 
Arteriovenous fistula creation 
Venepuncture for iron contrast 
and blood tests for biomarkers 
⋅ FeMRA & CMR 
Fistula 
creation 
Visit 1 
Day 0 
Visit 1 
Day 0 
Venepuncture for iron contrast 
⋅ FeMRA	&	CMR	
Patient recruited to study. 
Informed consent (Form A) 
Venepuncture for iron contrast 
and blood tests for biomarkers 
⋅ FeMRA & CMR 
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1.	Background	
	
Conventional	 vascular	 imaging	 techniques	 are	 often	 either	 contra-indicated	 or	 only	 used	 with	
caution	 in	 chronic	 kidney	 disease	 (CKD)	 patients	 due	 to	 their	 relative	 invasiveness,	 risks	 and	 cost.	
Computed	 tomography	 angiography	 (CTA)	 requires	 radiation	 and	 nephrotoxic	 iodinated	 contrast	
which	 may	 precipitate	 significant	 worsening	 of	 renal	 function	 and	 even	 prompt	 the	 need	 for	
institution	 of	 dialysis.	 Similarly,	 in	 patients	 receiving	 maintenance	 haemodialysis	 (HD),	 contrast	
administration	 has	 the	 potential	 risk	 of	 accelerating	 a	 decline	 in	 residual	 kidney	 function.	
Additionally,	 CT	 has	 reduced	 accuracy	 for	 arterial	 diagnosis	 in	 the	 presence	 of	 arteriosclerotic	
calcification	which	is	extremely	common	in	these	patients.	Magnetic	resonance	angiography	(MRA)	
in	 patients	 with	 end-stage	 renal	 disease	 (ESRD)	 using	 linear	 chelate	 gadolinium-based	 contrast	
agents	 has	 been	 associated	 with	 the	 rare	 disease	 ‘nephrogenic	 systemic	 fibrosis’[1].	 Alternative	
imaging	 methods	 also	 have	 drawbacks:	 for	 example,	 this	 frail	 patient	 group	 has	 a	 higher	 risk	 of	
complications	 from	 conventional	 invasive	 catheter-based	 angiography	 and	 calcification	 interferes	
with	duplex	ultrasound	assessment	of	 the	peripheral	arterial	vasculature.	Other	 tests	such	as	non-
contrast	MRA	methods	are	 less	accurate	and	ultrasound	 is	often	not	appropriate	 for	evaluation	of	
the	deep	vessels	of	the	thorax,	abdomen	and	pelvis.	
	
1.1 Evaluation	of	the	potential	kidney	transplant	recipient	
Kidney	 transplantation	 is	 the	 treatment	of	 choice	 for	most	patients	with	ESRD.	A	 large	number	of	
potential	kidney	transplant	recipients	with	established	renal	failure	have	peripheral	vascular	disease	
and	need	additional	tests	to	characterise	the	vessels	before	placement	of	a	kidney	graft.	CTA	of	the	
aortoiliac	 vasculature	 for	 identification	 of	 calcifications	 of	 the	 iliac	 arterial	 sector	 allows	 better	
recipient	selection	and	accurate	planning	 for	 the	vascular	anastomosis	and	placement	of	 the	renal	
graft[2].	
	
Until	now,	the	widespread	use	of	CTA	in	the	workup	of	the	potential	renal	transplant	recipient	has	
been	 limited	 because	 of	 concerns	 of	 contrast-induced	 acute	 kidney	 injury	 (CI-AKI),	 especially	 in	
predialysis	 patients.	 In	 addition,	 CTA	 can	 be	 limited	 by	 arterial	 calcification	 and	 also	 does	 not	
robustly	evaluate	venous	anatomy.	
	
1.2	Vascular	mapping	before	access	creation	
Doppler	 ultrasound	 is	 routinely	 used	 to	 allow	 proper	 selection	 of	 a	 target	 vessel	 with	 adequate	
luminal	 diameter	 to	 improve	 access	 outcome.	 This	 is	 readily	 available	 and	 cheap	 but	 has	 a	major	
limitation	which	 is	 the	 relative	 inability	 to	 assess	 central	 vein	 patency.	 Central	 vein	 stenosis	 (CVS)	
occurs	 in	over	40%	of	patients	with	previous	percutaneous	 line	 insertions	for	dialysis[3]	and	digital	
subtraction	angiography	(DSA)	is	the	gold	standard	for	patients	at	risk	of	CVS.	However,	for	optimum	
results	DSA	requires	bilateral	venous	cannullation	with	good	caliber	cannulas	to	allow	rapid	injection	
of	contrast	to	opacify	the	central	veins,	and	this	can	be	challenging	in	CKD	patients.	
	
1.3	Vascular	access	surveillance	
Doppler	US	may	be	useful	for	surveillance	of	arteriovenous	fistulas	(AVF)[4].	In	a	systematic	review,	
4	randomised	trials	evaluated	access	flow-based	monitoring	in	native	AVFs[5].	Although	access	blood	
flow	screening	with	Doppler	US	prevented	access	 thrombosis	 in	AVFs,	 it	did	not	reduce	the	risk	of	
access	loss	or	extent	of	resource	use.	Despite	limited	data,	Doppler	US	has	become	the	standard	of	
	12	
	
practice	 for	 fistula	 surveillance	 with	 an	 increasing	 number	 of	 HD	 centres	 implementing	 fistula	
surveillance	programs.	
	
Polytetrafluoroethylene	 (PTFE)	 grafts	 are	used	 for	HD	 in	patients	with	 limited	options	 for	 a	native	
access.	 Their	 survival	 is	 similar	 or	 even	 better	 compared	 to	 AVFs	 with	 1-year	 patency	 of	
approximately	 70%[6]	 though	 they	 are	 typically	 complicated	 by	 thrombosis	 requiring	 multiple	
procedures	 to	 restore	 patency.	 Different	methodologies	 are	 currently	 being	 used	 for	 surveillance	
and	monitoring	 depending	 upon	 local	 practice	 and	 expertise.	 Doppler	 ultrasound	 is	 probably	 the	
most	reproducible	and	accurate	arteriovenous	graft	(AVG)	surveillance	method	but	has	low	accuracy	
of	 identifying	 central	 vein	 stenotic	 lesions.	 Graftogram	 with	 DSA	 which	 is	 the	 conventional	
angiography	technique	has	the	advantages	of	high	spatial	and	temporal	resolution	and	the	ability	to	
intervene	 but	 is	 invasive	 with	 the	 risk	 of	 vascular	 injury	 and	 stroke,	 does	 not	 provide	 a	 three–
dimensional	 representation	 of	 what	 can	 be	 complex	 anatomy,	 and	 requires	 the	 use	 of	 iodinated	
contrast	and	ionising	radiation.	
	
1.4	Associations	between	cardiac	function	and	vascular	access	
Cardiovascular	disease	is	a	well-known	predictor	of	fistula	failure	to	mature	(FTM)[7]	but	the	role	of	
a	low	cardiac	output	state	before	fistula	creation	has	not	been	investigated	sufficiently.	An	inability	
of	 the	 heart	 to	 increase	 the	 cardiac	 output	 following	 fistula	 creation	 may	 lead	 to	 hypotension,	
reduced	fistula	flow	and	subsequent	failure	of	maturation.			
	
On	 the	 other	 hand,	 it	 is	 well	 established	 that	 creation	 of	 arteriovenous	 access	 for	 dialysis	 has	
significant	effects	on	both	systolic	and	diastolic	function.	The	fistula	or	graft	adds	a	 low	resistance,	
high-compliance	venous	compartment	to	the	central	arterial	system.	It	is	associated	with	increased	
blood	flow,	pulmonary	hypertension,	and	cardiac	output.	Although	usually	clinically	insignificant,	the	
increased	cardiac	output	and	blood	flow	may	be	so	great	at	times	that	they	result	 in	overt	cardiac	
failure[8,	9].	This	is	particularly	true	if	the	patient	has	underlying	heart	disease	and/or	the	access	has	
flows	greater	than	2000	mL/min[10].	
	
1.5	Markers	of	endothelial	dysfunction	
In	HD	patients,	complex	coagulation	abnormalities	occur,	ranging	from	bleeding	to	thrombosis.	On	
the	 one	 hand,	 the	 enhanced	 bleeding	 tendency	 in	 these	 patients	 is	 primarily	 based	 on	 functional	
platelet	abnormalities	and	defective	adhesion	to	the	vessel	wall[11].	On	the	other	hand,	a	variety	of	
coagulation	abnormalities	contribute	to	an	increased	thrombotic	tendency.		
	
Cytokines	and	pro-inflammatory	 factors	have	been	shown	to	play	central	 roles	 in	 the	activation	of	
acute	 and	 chronic	 vascular	 responses	 to	 injury[12].	 For	 example,	 thrombin	 secreted	 by	 activated	
platelets	 adhering	 to	 the	 injured	 endothelium	 triggers	 the	 release	 of	 fibroblast	 growth	 factors,	
stimulating	 smooth	 muscle	 cells	 (SMC)	 mitogenesis	 and	 chemotaxis.	 Transforming	 growth	 factor	
beta	 (TGFß),	 a	 pleiotropic	 cytokine,	 promotes	 intimal	 hyperplasia	 by	 augmenting	 neointimal	 cell	
proliferation,	 inducing	 SMC	migration	and	 stimulating	 the	 secretion	of	 fibrotic	 extracellular	matrix	
proteins[13].	 Patients	 with	 renal	 disease	 undergoing	 HD	 have	 a	 raised	 inflammatory	 profile	 with	
significantly	 increased	 high	 sensitivity	 C-reactive	 protein	 (hs-CRP),	 serum	 tumor	 necrosis	 factor-a	
(TNF-α),	 interleukin-1	 (IL-1),	 soluble	 interleukin-2	 receptor	 (s-IL2R),	 interleukin-6	 (IL-6),	 monocyte	
chemoattractant	 protein-1	 (MCP-1),	 vascular	 cell	 adhesion	molecule	 1	 (VCAM-1)	 and	 intercellular	
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adhesion	molecule	 1	 (ICAM-1),	 as	 well	 as	 increased	 expression	 of	 the	 pro-inflammatory	 receptor	
Toll-like	receptor	4	(TLR-4)[14-18].	
	
1.6	Ferumoxytol	enhanced	Magnetic	Resonance	Angiography	(FeMRA)	
Ferumoxytol	 is	 an	 ultrasmall	 superparamagnetic	 iron	 oxide	 (USPIO)	 particle	 encapsulated	 by	 a	
semisynthetic	carbohydrate	with	properties	that	can	be	used	for	diagnosis	and	therapy.	Ferumoxytol	
was	initially	developed	as	a	MRI	contrast	agent	and	filed	for	patent	as	this	on	March	8th	2000	(patent	
published	2003)[19].	However,	 interest	 in	Ferumoxytol	as	a	therapeutic	agent	for	the	treatment	of	
iron	deficiency	anaemia	 (IDA)	eclipsed	 its	use	as	magnetic	 resonance	 (MRI)	 contrast	agent.	During	
the	 last	 decade,	 the	 identification	 of	 the	 association	 of	 nephrogenic	 systemic	 fibrosis	 (NSF)	 with	
linear	 chelate	 gadolinium-based	 contrast	 agent	 administration	 to	 patients	 with	 advanced	 kidney	
disease	has	led	to	renewed	interest	in	Ferumoxytol	as	a	contrast	agent	due	to	its	superparamagnetic	
properties[20-22].	
	
Ferumoxytol	is	licensed	in	the	USA	and	Canada	for	treating	IDA	in	the	setting	of	CKD	[23]	but	not	for	
clinical	diagnostic	 imaging.	 It	has	gained	appeal	as	a	MRI	contrast	agent	 in	patients	with	estimated	
glomerular	filtration	rates	<30mL/min/1.73m2	in	whom	other	imaging	modalities	are	contraindicated	
or	can	only	be	used	with	caution	and	there	are	reports	in	the	literature	for	its	safe	use	and	utility	in	
both	 adult[24]	 and	pediatric[25]	 patients	with	CKD.	 Ferumoxytol	metabolism	 is	 not	dependent	on	
kidney	function,	but	rather	is	removed	from	the	circulation	by	the	reticuloendothelial	system	of	the	
liver,	 spleen,	 and	 bone	 marrow.	 Additionally,	 the	 prolonged	 intravascular	 half-life	 (>14	 hours)	 of	
Ferumoxytol	allows	for	longer	image	acquisition	and	repeat	imaging,	if	necessary[21,	26,	27].	
	
The	typical	dose	used	for	 imaging	 is	15-40%	that	for	 iron	replacement,	therefore	the	safety	profile	
for	imaging	is	more	attractive	than	for	iron	replacement.	Ferumoxytol	has	been	licensed	in	the	USA	
and	 Canada	 for	 use	 in	 patients	 with	 kidney	 failure	 and	 this	 has	 important	 implications	 in	 clinical	
practice	since	the	agent	can	be	used	in	patients	with	compromised	renal	function	where	there	is	a	
pressing	 clinical	 question	 but	 no	 other	 viable	 angiographic	 option.	We,	 and	 others,	 have	 studied	
vascular	 iron	MRA	using	Ferumoxytol	as	contrast	for	clinically	 indicated	scans[28]	(examples	of	our	
scans	below).	
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Left	-	Iliac	vessels	with	iron	MRA	in	a	transplant	recipient.	Right	-	Iron	MRA	of	central	vessels.	
	
	
2.	Rationale	
	
Use	of	conventional	contrast	agents,	both	iodinated	or	gadolinium	based,	in	patients	with	late-stage	
CKD	are	 limited	by	 the	 risks	 for	additional	acute	kidney	 injury	and	NSF,	 respectively,	 that	must	be	
balanced	by	the	critical	nature	of	the	radiologic	study	for	the	well-being	of	the	patient.	In	addition,	
current	 techniques	have	 reduced	accuracy	 for	arterial	diagnosis	 in	 the	presence	of	arteriosclerotic	
calcification	or	have	 limitations	 in	assessing	central	vein	patency.	 In	 these	patients,	Ferumoxytol	 is	
an	alternative	agent	for	cardiovascular	assessment,	including	vessel	patency	and	course.		
	
We	 are	 proposing	 to	 apply	 novel	 techniques	 with	 MRA	 using	 intravenous	 iron	 whilst	 planning	
transplantation	or	haemodialysis	for	renal	replacement	therapy.	The	“Use	of	Ferumoxytol	enhanced	
Magnetic	Resonance	Angiography	for	cardiovascular	assessment	in	late-stage	chronic	kidney	disease	
(FeMRA	 in	 CKD)	 study”	 is	 a	 single	 centre	 prospective	 cohort	 study	designed	 to	 compare	 routinely	
used	imagining	techniques	with	FeMRA	in	patients	with	severely	impaired	renal	function.	
	
Study	 participants	 undergoing	 standard	 imaging	 tests	 as	 part	 of	 their	 clinical	 care	 will	 also	 have	
FeMRA.	We	will	compare	outcomes	of	interest	including	quality	of	image	and	diagnostic	accuracy	in	
a	 head-to-head	 design.	 The	 additional	 information	 gained	 will	 determine	 if	 Ferumoxytol-based	
vascular	 imaging	 has	 the	 potential	 to	 offer	 a	 practical	 solution	 to	 both	 gadolinium-based	 and	
iodinated	contrast	agents	when	assessing	vessel	anatomy	in	patients	with	late-stage	CKD.	
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3.	Study	Objectives	
	
The	 FeMRA	 in	 CKD	 study	 is	 designed	 to	 compare	 standard	 with	 novel	 imaging	 techniques	 for	
cardiovascular	assessment	in	late-stage	CKD	with	the	objective	to	provide	a	better	imaging	modality.		
	
3.1	Primary	objectives	
	
1. Vascular	 anatomy	 before	 implantation	 of	 a	 kidney	 graft	 using	 routine	 and	 novel	 imaging	
techniques.	
	
2. Vascular	 anatomy	 before	 and	 after	 fistula	 creation	 using	 routine	 and	 novel	 imaging	
techniques.	
	
3. Vascular	anatomy	before	and	after	synthetic	graft	creation	using	routine	and	novel	imaging	
techniques.	
	
3.2	Secondary	objectives	
1. Assessment	of	cardiac	anatomy,	function,	and	myocardial	perfusion	before	implantation	of	a	
kidney	graft	using	novel	imaging	techniques.	
	
2. Anatomical	 predictors	 of	 US-based	 fistula	 maturation	 using	 routine	 and	 novel	 imaging	
techniques.	
	
3. Assessment	of	cardiac	anatomy,	function,	and	myocardial	perfusion	before	and	after	fistula	
creation	using	novel	imaging	techniques.	
 
4. Assessment	 of	 cardiac	 anatomy,	 function,	 and	 myocardial	 perfusion	 before	 and	 after	
synthetic	graft	creation	using	novel	imaging	techniques.	
	
5. Assessment	 of	 cardiac	 morphology,	 coronary	 blood	 supply,	 microvascular	 perfusion,	 and	
tissue	characterisation	using	novel	imaging	techniques	(sub-study).	
	
	
4.	Study	Hypotheses	
	
These	hypotheses	will	be	tested:	
	
A.	Vascular	anatomy	
	
1. FeMRA	 is	 superior	 to	 CTA	 for	 characterisation	 of	 abdominal	 and	 aortoiliac	 anatomy	 (pre-
transplant	assessment)	before	implantation	of	a	kidney	graft.	
	
2. FeMRA	 is	 superior	 to	 Doppler	 US	 for	 characterisation	 of	 upper	 limb	 vascular	 anatomy	
(vascular	mapping)	before	fistula	creation.	
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3. FeMRA	 is	 superior	 to	 Doppler	 US	 for	 characterisation	 of	 upper	 limb	 vascular	 anatomy	
(vascular	mapping)	before	synthetic	graft	creation.	
	
4. FeMRA	 is	 superior	 to	 Doppler	 US	 for	 characterisation	 of	 upper	 limb	 vascular	 anatomy	
(vascular	mapping)	before	fistula	creation	in	patients	with	suspected	CVS.	
	
5. FeMRA	 is	 superior	 to	 Doppler	 US	 for	 characterisation	 of	 upper	 limb	 vascular	 anatomy	
(vascular	mapping)	before	synthetic	graft	creation	in	patients	with	suspected	CVS.	
	
6. FeMRA	 is	 superior	 to	 Doppler	 US	 for	 characterisation	 of	 fistula	 arm	 vascular	 anatomy	
(surveillance)	at	6	weeks	after	fistula	creation.	
	
7. FeMRA	 is	 superior	 to	 DSA	 graftogram	 for	 characterisation	 of	 graft	 arm	 vascular	 anatomy	
(surveillance)	at	6	weeks	after	synthetic	graft	creation.	
	
B.	Anatomical	predictors	of	outcomes	
	
1. Anatomical	characteristics	of	vessels	such	as	diameter	or	anatomical	 lesions	prior	to	fistula	
(or	graft)	creation	are	determinants	of	fistula	(or	graft)	outcomes.	
	
2. Early	post-operative	changes	in	vessel	diameter	predict	fistula	(or	graft)	outcomes.	
	
3. FeMRA	is	superior	to	Doppler	US	for	identification	of	pre-operative	subtle	anatomical	lesions	
(vascular	mapping)	associated	with	fistula	(or	graft)	outcomes.	
	
4. FeMRA	is	superior	to	Doppler	US	for	identification	of	pre-operative	subtle	anatomical	lesions	
(vascular	 mapping)	 associated	 with	 fistula	 (or	 graft)	 outcomes	 in	 patients	 with	 suspected	
CVS.	
 
5. FeMRA	 is	 superior	 to	Doppler	US	 for	 assessment	 of	 fistula	 lumen,	 inflow	 artery	 diameter,	
and	average	draining	vein	diameter	as	surrogates	for	fistula	maturation	and	usability.	
 
6. FeMRA	is	superior	to	Doppler	US	for	identification	of	early	post-operative	subtle	anatomical	
lesions	(surveillance)	associated	with	fistula	outcome.	
	
7. FeMRA	 is	 superior	 to	 DSA	 graftogram	 for	 identification	 of	 early	 post-operative	 subtle	
anatomical	lesions	(surveillance)	associated	with	graft	outcome.	
	
C.	Cardiac	imaging	
1. FeMRA	 is	 useful	 in	 rapid	 MRI	 assessment	 of	 cardiac	 anatomy,	 function,	 and	 myocardial	
perfusion.		
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2. FeMRA	 has	 the	 advantage	 of	 complete	 cardiovascular	 assessment	 (heart,	 central,	 and	
peripheral	 vasculature)	 using	 a	 single	 imaging	 modality	 when	 used	 for	 pre-transplant	
assessment.	
	
3. Low	cardiac	output	state	before	 fistula	 (or	graft)	creation	 is	a	predictor	of	 fistula	 (or	graft)	
outcomes.	
	
4. Successful	fistula	(or	graft)	creation	is	associated	with	high-output	cardiac	failure.	
	
5. Successful	 fistula	 (or	 graft)	 creation	 is	 associated	 with	 a	 favorable	 effect	 in	 cardiac	
microcirculation	kinetics	(pre-conditioning	hypothesis).	
	
6. Patients	who	have	unsuccessful	fistula	(or	graft)	operation	exhibit	no	recordable	changes	in	
cardiac	microcirculation.	
 
7. FeMRA	is	useful	in	assessment	of	cardiac	morphology,	coronary	blood	supply,	microvascular	
perfusion,	and	tissue	characterisation	(sub-study).	
	
D.	Implications	in	clinical	practice	
	
1. FeMRA	 is	 the	 imaging	modality	 of	 choice	 for	 characterisation	 of	 abdominal	 and	 aortoiliac	
anatomy	(pre-transplant	assessment)	before	implantation	of	a	kidney	graft.	
	
2. FeMRA	is	the	imaging	modality	of	choice	for	characterisation	of	vascular	anatomy	(vascular	
mapping)	before	fistula	(or	graft)	creation	in	patients	with	suspected	CVS.	
	
3. FeMRA	 is	 the	 imaging	 modality	 of	 choice	 for	 characterisation	 of	 vascular	 anatomy	
(surveillance)	early	post-operatively	after	synthetic	graft	creation.	
	
	
5.	Study	Design	
	
5.1	Data	collection	and	study	procedures	
	
Pre-operative	procedures	
	
Ø Eligibility	screening	
Ø Informed	consent	
Ø Baseline	clinical	data	collection	
§ Demographics	
§ Comorbidities	
§ Medications	
§ Dialysis	history	
§ Vascular	access	history	
Ø Provide	patient	alert	card	
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Ø Pregnancy	test	before	Ferumoxytol	administration	for	women	of	child-bearing	potential	
Ø Vascular	mapping	 Ø Pre-transplant	assessment	
§ Ultrasound	vascular	mapping	or	DSA	for	
patients	with	suspected	CVS	(standard	care)	
§ CTA	abdominal	and	aortoiliac	
vasculature	(standard	care)	
§ FeMRA	fistula	(or	graft)	arm/central	veins	&	
CMR	(study	visit	1)	
§ FeMRA	abdominal/aortoiliac	vasculature	
&	CMR	(study	visit	1)	
§ Blood	samples	for	biomarkers	(study	visit	1)	 § Blood	samples	for	biomarkers	(study	visit	
1)	
	
Post-operative	procedures	
	
Ø Pregnancy	test	before	Ferumoxytol	administration	for	women	of	child-bearing	potential	
Ø Fistula	surveillance	 Ø Graft	surveillance	
§ 6-week	ultrasound	fistula	arm	
(standard	care)	
§ 6-week	DSA	graftogram		
(standard	care)	
§ 6-week	FeMRA	fistula	arm/central	
veins	&	CMR	(study	visit	2)	
§ 6-week	FeMRA	graftogram/central	veins	
&	CMR	(study	visit	2)	
§ Blood	samples	for	biomarkers	(study	
visit	2)	
§ Blood	samples	for	biomarkers	(study	visit	
2)	
Ø Imaging	surrogates	for	fistula	usability	
Ø Vascular	access	complications	and	fistula	procedures	data	collection	
Ø Fistula	use	and	abandonment	data	collection	
	
Sub-study	(optional)	
	
Ø Cardiac	4D	MRA	(no	additional	study	visit	required)	
	
5.2	Imaging	studies	and	blood	tests	
Pre-operative	 and	 post-operative	 FeMRAs	 will	 be	 performed	 by	 trained	 personnel	 using	
standardised	protocols.	 FeMRAs	will	 be	 reviewed	by	 the	 study	 radiologists	who	will	 be	blinded	 to	
other	 investigations.	 Standard	care	 imaging	 studies	will	 also	be	 reviewed	by	 the	 study	 radiologists	
who	will	be	blinded	to	the	FeMRA	findings.	An	independent	radiologist	that	is	not	directly	involved	in	
the	study	will	also	review	 images.	All	discrepancies	will	be	resolved	by	mutual	consensus	between	
the	radiologists.	
	
We	will	not	alter	our	routine	clinical	practice	which	involves	CTA	for	pre-transplant	assessment	when	
indicated,	ultrasound	vein	mapping	(or	invasive	angiography)	for	all	patients	before	vascular	access	
creation,	 US	 Doppler	 for	 fistula	 surveillance,	 and	 DSA	 graftogram	 for	 graft	 surveillance.	 All	 these	
tests	are	part	of	our	standard	care,	and	results	will	be	available	 for	clinical	use.	However,	FeMRAs	
will	not	be	made	available	to	clinicians	or	study	investigators	unless	there	is	a	finding	that	threatens	
the	participant’s	health	(e.g.	impending	rupture	of	pseudoaneurysm).		
	
The	 imaging	 studies	 will	 serve	 multiple	 functions	 including	 characterising	 the	 natural	 history	 of	
fistula	maturation	 and	delineating	 temporal	 changes	 that	 reflect	 physiological	 responses	 to	 fistula	
(or	 graft)	 creation.	 The	 6-week	 ultrasound	 (and	 FeMRA)	 will	 be	 used	 to	 predict	 imaging-based	
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anatomical	 maturation	 as	 a	 potential	 surrogate	 for	 clinical	 maturation.	 One	 study	 objective	 is	 to	
determine	 if	 FeMRA	 is	 superior	 to	 ultrasound	 in	 characterisation	 of	 blood	 vessel	 anatomy	 and	
demonstration	 of	 subtle	 arterial	 and	 venous	 changes	 prior	 to	 these	 having	 haemodynamic	
significance.	Another	objective	 is	 to	determine	 the	utility	of	 fistula	 luminal	diameter,	 inflow	artery	
diameter,	 and	 average	 draining	 vein	 diameter	 as	 composite	 surrogate	 outcomes	 for	 fistula	
maturation	and	usability.	
	
5.2.1	Ultrasound	vascular	mapping	
The	patients	will	receive	bilateral	upper	extremity	US	vascular	mapping	with	both	vein	and	arterial	
components.	Vein-US	mapping	 involves	measurement	of	vein	diameters	at	the	following	 locations:	
cephalic	 and	 basilic	 veins	 at	 the	 proximal	 upper	 arm,	 mid-upper	 arm,	 distal	 upper	 arm,	 and	
antecubital	fossa;	cephalic	vein	at	the	proximal	forearm,	mid-forearm,	distal	forearm,	and	the	wrist.	
Compressibility	 and	 presence	 of	 thrombus	 as	 well	 as	 continuity	 to	 the	 upper	 arm	 deep	 venous	
vasculature	 will	 be	 assessed.	 Vein-US	 examinations	 will	 be	 performed	 with	 the	 patient	 supine	 at	
ambient	temperature	and	a	rubber	tourniquet	in	place.	Specific	arterial-US	examination	components	
include:	diameter	of	the	brachial	artery	at	the	antecubital	fossa,	diameter	of	the	radial	artery	at	the	
wrist,	 level	of	brachial	artery	bifurcation	 relative	 to	 the	antecubital	 fossa,	 results	of	 the	US	Allen's	
test,	 and	 arterial	 waveform	 tracing	 at	 the	 antecubital	 fossa	 brachial	 artery	 and	 the	 wrist	 radial	
artery.	The	US	Allen's	test	will	be	performed	as	described	by	the	American	Institute	of	Ultrasound	in	
Medicine	(AIUM)	Practice	Guidelines[29]	by	occluding	the	radial	artery	near	the	wrist	and	placing	the	
US	 probe	 distal	 to	 the	 occlusion.	 Retrograde	 flow	 indicates	 a	 positive	 Allen's	 test	 and	 a	 patent	
palmar	arch.	Lack	of	flow	indicates	a	negative	Allen's	test	and	an	incomplete	palmar	arch.	
	
Findings	on	vascular	mapping	that	would	be	against	 fistula	creation	 include	cephalic	or	basilic	vein	
<2.5mm,	vein	not	continuous	to	upper	arm,	radial	or	brachial	artery	<2.0mm,	an	incomplete	palmar	
arch	by	US	Allen's	test,	blunted	radial	artery	waveforms,	and	brachial	artery	bifurcations	above	the	
antecubital	 fossa.	 The	 overall	 plan	 for	 the	 site	 of	 fistula	 creation	 will	 be	 based	 on	 both	 vascular	
mapping	findings	and	clinical	judgment	as	opposed	to	hard	arterial	anatomic	criteria	alone.	
	
5.2.2	Ferumoxytol	enhanced	magnetic	resonance	angiography	
Patients	 will	 undergo	 MRA	 with	 Ferumoxytol	 administered	 in	 an	 appropriate	 setting	 under	
supervision	 of	 trained	 medical	 personnel	 with	 appropriate	 monitoring	 and	 resuscitation	 facilities	
immediately	available.	
	
We	 are	 proposing	 to	 perform	 FeMRA	 to	 assess	 central	 and	 peripheral	 vessels,	 and	 the	 heart	
depending	on	 the	 indication.	 Images	will	be	acquired	while	 the	patient	 remains	 supine	 in	 the	MRI	
system	 (3T	 Prisma	 at	 Glasgow	 Clinical	 Research	 Facility	 on	 Queen	 Elizabeth	 University	 Hospital	
campus)	with	local	phased	array	imaging	coils.	The	scan	will	last	for	approximately	45	minutes.	
	
We	will	place	an	 intravenous	cannula	during	 the	course	of	 the	 research	scan	 for	administration	of	
the	dilute	Ferumoxytol	 infusion.	Blood	samples	will	be	obtained	at	the	time	of	cannula	placement.	
The	 cannula	 will	 only	 be	 in	 place	 for	 an	 hour	 or	 less,	 thus	 rendering	 negligible	 any	 potential	
complications	relating	to	infection.		
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The	 patient	 will	 be	 monitored	 by	 medical	 and	 radiographic	 staff	 at	 baseline,	 during,	 and	 for	 a	
minimum	 period	 of	 30	 minutes	 following	 termination	 of	 infusion.	 Patients	 will	 be	 instructed	 to	
immediately	alert	the	operator	should	they	have	any	feelings	of	discomfort	at	any	time.	Patients	will	
be	continuously	monitored	by	pulse	oximetry	while	in	the	MRI	scanner	and	will	have	blood	pressure	
and	 pulse	 measured	 before	 and	 after	 infusions.	 Administration	 of	 other	 medications	 that	 could	
potentially	cause	serious	hypersensitivity	 reactions	and/or	hypotension,	 such	as	chemotherapeutic	
agents	 or	 monoclonal	 antibodies	 will	 not	 be	 administered	 for	 at	 least	 30	 minutes	 after	
administration	of	Ferumoxytol.	In	order	to	avoid	the	situation	that	patients	will	have	completed	their	
scanning	and	would	experience	a	reaction	after	leaving	the	imaging	suite,	we	will	require	subjects	to	
remain	under	observation	for	a	minimum	period	of	30	minutes	following	injection	even	if	they	are	
already	 out	 of	 the	 scanner.	 Once	 out	 of	 the	 scanner,	 patients	 will	 remain	 in	 a	 reclining	 or	 semi-
reclining	 position.	 Observation	 for	 the	 full	 30	 minutes	 following	 the	 contrast	 injection,	 i.e.,	 both	
while	the	patient	is	in	the	scanner	and	following	that	will	be	done	by	the	doctors	directly	involved	in	
the	study	who	are	aware	of	the	study	protocol,	and	who	are	trained	on	procedures	to	be	followed	in	
the	 event	 of	 any	 reaction.	 The	 same	 precautions	 will	 be	 taken	 for	 each	 scan,	 even	 if	 no	
hypersensitivity	 reaction	 occurred	 after	 the	 first	 scan.	 Should	 the	 patient	 experience	 signs	 or	
symptoms	of	hypersensitivity	they	will	be	observed	until	clinically	stable.			
	
The	imaging	protocol	will	be	similar	to	that	of	standard	MRA	studies	with	gadolinium-based	contrast	
agents.	Imaging	will	be	performed	on	a	3T	Prisma	(Siemens)	clinical	MRI	system.	A	maximum	dose	of	
3mg	 of	 Ferumoxytol/kg	 of	 patient	 weight	 will	 be	 delivered	 (not	 to	 exceed	 300mg).	 In	 all	 cases	
Ferumoxytol	will	be	diluted	to	a	concentration	no	greater	than	1	part	Ferumoxytol	to	4	parts	0.9%	
sodium	 chloride.	 Ferumoxytol	 administration	 is	 controlled	 by	 a	 sophisticated	 MRI	 compatible	
infusion	pump	for	precise	control	over	infusion	rate.	When	given	for	treatment	of	IDA,	the	licensed	
dose	of	Ferumoxytol	 is	an	 initial	510mg	dose	administered	as	an	 intravenous	 infusion	 in	50-200mL	
0.9%	sodium	chloride	or	5%	Dextrose	over	at	least	15	minutes,	followed	by	a	second	510mg	dose	3	
to	8	days	later.	When	administered	for	imaging,	Ferumoxytol	will	be	given	in	a	continuous	infusion	
of	 diluted	 agent	 over	 at	 least	 15	minutes	 to	 comply	with	 the	 FDA	 recommendations,	 though	 the	
diagnostic	dose	is	less	than	half	the	therapeutic	dose	(210mg	for	a	70kg	patient).	A	20ml	saline	flush	
will	be	injected	following	administration	of	the	full	dose	of	Ferumoxytol.	Patients	will	be	divided	into	
13	dose	bands	according	to	body	weight	using	increments	of	5kg.	The	dose	given	within	each	weight	
group	 will	 be	 rounded	 up	 to	 the	 dose	 required	 for	 the	 upper	 limit	 of	 the	 group.	 The	 average	
rounding	is	a	6%	increase	in	dose	(range	4-13%)	compared	to	actual	dose	at	the	lowest	weight	of	the	
band.	 For	 patients	 exceeding	 100kg,	 a	 total	 dose	 of	 300mg	will	 be	 administered	 irrespectively	 of	
weight.	Details	of	the	total	dose	and	infusions	volumes	to	be	administered	for	each	dose	band	are	
shown	in	Table	1.		
	
Patients	will	be	asked	if	they	wish	to	have	a	second	scan	at	the	same	day	as	part	of	a	sub-study.	This	
is	 optional	 and	will	 not	 affect	 patients’	 participation	 in	 the	main	 study.	 In	 this	 sub-study,	we	will	
acquire	 additional	 cardiac	MRI	 scans	 at	 our	University	MRI	 site	 (Glasgow	Cardiovascular	 Research	
Centre,	British	Heart	Foundation	Centre	of	Excellence).	This	additional	scan	will	give	us	information	
about	 the	 status	 of	 epicardial	 coronary	 vessels	 and	 provide	 a	 detailed	 4D	 magnetic	 resonance	
angiography	dataset	(3D	coronary	vessel	tree	in	multiple	ECG	phases).	This	method	was	developed	
by	our	collaborators	at	 the	Cedars	Sinai	Hospital,	USA,	and	will	 allow	us	 to	have	a	complete,	non-
invasive	assessment	of	 the	heart	morphology	and	different	 levels	of	 function:	 from	the	patency	of	
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the	 coronary	 blood	 supply,	 microvascular	 perfusion,	 tissue	 characterisation	 using	 T1/T2/T2*	
mapping	to	wall	motion,	and	feature	tracking	analysis	of	myocardial	strain.	The	protocol	will	include	
localisers,	T1/T2	and	T2*	maps,	self-navigated	4D	MRA	sequence	and	4D	flow	assessment.	
	
At	time	of	consent,	patients	will	be	asked	if	they	wish	to	have	the	additional	coronary	4D	MRA	scan	
at	 the	 British	 Heart	 Foundation	 scanner	 (following	 their	 FeMRA	 scan	 at	 the	 Queen	 Elizabeth	
University	Hospital).	No	additional	contrast	administration	is	required	for	the	4D	coronary	MRA	scan	
which	will	 last	 for	 approximately	 60	minutes.	 Patients	 that	will	 consent	will	 be	 offered	 lunch	 and	
transport	 to	 the	University	site.	The	4D	MRA	scan	will	 take	place	2-4	hours	after	 the	FeMRA	scan.	
This	scan	will	also	be	supervised	by	the	doctors	directly	involved	in	the	study	who	are	aware	of	the	
study	protocol,	and	who	are	trained	on	procedures	to	be	followed	in	the	event	of	any	reaction.	
	
5.2.3	Blood	processing	and	storage	
Venous	blood	will	 be	 collected	at	baseline	and	at	6	weeks	after	 fistula	 (or	 graft)	 creation.	Venous	
blood	will	be	analysed	for	vascular	biomarkers,	which	may	include	TGFß,	high	sensitivity	troponin	I	
(hs-TNI),	pentraxin	3,	 ICAM-1,	von	Willebrand	factor	 (vWF),	 tissue	plasminogen	activator	 (tPA)	and	
plasminogen	 activator	 inhibitor-1	 (PAI-1).	 Novel	 biomarkers	 of	 endothelial	 function	 continue	 to	
emerge	and	we	 shall	 seek	 the	permission	of	 research	participants	 for	 stored	blood	 samples	 to	be	
analysed	in	the	future.	
	
The	total	amount	of	research	blood	taken	at	each	visit	will	be	no	more	than	30ml.	Samples	will	be	
anonymised	 in	 the	 laboratory.	 No	 identifiable	 details	 will	 be	 collected	 with	 the	 samples.	 If	
agreement	is	given	for	potential	novel	biomarkers,	10ml	of	blood	will	be	anonymously	stored	–	any	
subsequent	 analysis	 of	 these	 samples	will	 be	 subject	 to	 approval	 of	 a	 Research	 Ethics	 Committee	
prior	to	analysis.	On	the	completion	of	this	study,	the	blood	samples	will	be	transferred	and	retained	
to	 the	NHS	Greater	Glasgow	&	Clyde	biorepository.	This	will	 enable	 the	 samples	 to	be	 stored	and	
used	within	a	suitable	research	governance	framework.	
	
5.3	Study	visits	
Each	patient	will	have	one	(if	assessed	as	a	potential	kidney	transplant	recipient)	or	two	(if	planned	
for	vascular	access	creation)	study	visits.	We	are	proposing	to	perform	FeMRA	at	6	weeks	following	
fistula	 creation	 as	 at	 that	 point	 it	 is	 generally	 apparent	 whether	 a	 fistula	 will	 mature	 without	
additional	intervention[30,	31].	
	
Participants	will	 be	provided	with	a	patient	 information	 sheet	 (PIS)	 and	given	at	 least	24	hours	 to	
consider	 their	 response	 before	 consent	 is	 taken	 and	 a	 screening	 visit	 is	 performed	 to	 check	 their	
eligibility	by	all	the	criteria.	Standard	imaging	tests	will	take	place	as	part	of	the	routine	clinical	care.	
The	FeMRA	scan	will	be	requested	and	scheduled	at	a	suitable	date	and	time	-	usually	the	scan	will	
be	 within	 two	 weeks	 after	 they	 sign	 the	 consent	 form.	 For	 practical	 reasons,	 the	 scans	 will	 be	
booked	 in	 different	 dates.	 There	 is	 not	 a	minimum	elapsed	 time	 recommended	between	 the	 two	
scans	as	they	are	using	different	contrast	agents	that	are	not	interfering	with	each	other’s	 imaging	
quality,	but	we	will	ensure	they	will	occur	at	least	48	hours	apart	to	have	enough	time	to	monitor	for	
potential	unexpected	adverse	events.	We	will	also	schedule	all	scans	on	non-dialysis	days	for	those	
patients	who	are	on	dialysis.	
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All	study	investigations	will	take	place	at	the	Queen	Elizabeth	University	Hospital.	For	patients	that	
will	consent	to	have	the	cardiac	4D	MRA	scan	in	addition	to	the	FeMRA	scan	as	part	of	the	sub-study,	
this	will	take	place	at	the	University	MRI	site	(Glasgow	Cardiovascular	Research	Centre,	British	Heart	
Foundation	Centre	of	Excellence)	the	same	day.	Travel	expenses	will	be	provided	for	study	visits.	In	
addition,	lunch	and	transport	to	the	University	site	will	be	offered	for	the	patients	having	the	cardiac	
4D	MRA	scan.	
	
5.4	Duration	of	participation	
The	 participant	 would	 only	 be	 in	 the	 study	 in	 person	 up	 to	 the	 completion	 of	 the	 study	
investigations.	 This	means	one	day	 for	 the	patients	 in	 group	A	 (for	 the	day	of	 their	MRI	 scan	and	
blood	samples)	and	6	weeks	for	the	patients	in	group	B	(up	until	their	second	MRA	scan	and	blood	
samples).	
Unless	they	withdraw	from	the	study,	the	patients	will	remain	in	the	study	for	the	entire	duration	of	
the	 follow	 up	 for	 up	 to	 2	 years.	 Follow	 up	 involves	 regular	 review	 of	 the	 medical	 records	 for	
identification	of	any	outcomes	of	interest.	Their	imaging	would	remain	available	for	review	after	the	
end	of	the	study.	As	the	clinicians	should	be	blinded	to	the	results	of	the	investigational	scan	(unless	
there	is	a	finding	that	threatens	the	participant’s	health),	we	will	ensure	that	the	FeMRA	scans	will	
be	reported	no	sooner	than	6	weeks	after	they	are	performed.	The	images	will	be	uploaded	to	the	
Scottish	National	Picture	Archive	and	Communication	System	(PACS)	immediately	after	the	scans	are	
carried	out.	
		
6.	Study	Population	
	
The	 study	 is	 expected	 to	 enroll	 40	 participants	 undergoing	 imaging	 for	 pre-transplant	 candidacy	
assessment	and	60	undergoing	creation	of	new	fistula	(or	graft	)	for	dialysis.	
	
6.1	Inclusion	criteria	
	
1. Planned	surgical	creation	of	an	autogenous	upper-extremity	fistula	or	synthetic	graft.	
AND	
Current	treatment	with	maintenance	haemodialysis	or	anticipated	treatment	with	maintenance	
haemodialysis	within	6	months	after	planned	fistula	or	graft	creation	surgery.	
	
OR	
Planned	imaging	of	abdominopelvic	vasculature	as	part	of	pre-transplant	assessment.	
	
2. Anticipated	ability	to	comply	with	study	procedures.	
	
3. Ability	to	provide	informed	consent.	
	
6.2	Exclusion	criteria	
	
1. Life	expectancy	≤6	months.	
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2. Frail,	elderly	patients	with	multiple	or	serious	co-morbidities	(doctor’s	discretion).	
 
3. Pregnancy,	 lactation	 or	 women	 of	 child-bearing	 potential	 not	 willing	 to	 use	 effective	
contraception	for	the	duration	of	the	study.	
	
Childbearing	potential	is	defined	as	women	who	have	experienced	menarche	and	who	have	not	
undergone	successful	surgical	sterilisation	or	who	are	not	post-menopausal	(irregular	menstrual	
periods,	 or	 amenorrhoea	 >12	 months,	 with	 serum	 follicle	 stimulating	 hormone	 (FSH)	
>35mIU/ml;	women	taking	hormone	replacement	therapy	(HRT)).	
	
Women	of	childbearing	potential	will	be	eligible	if	they	are	willing	to	use	effective	contraception	
(combined	 oral	 contraceptives,	 progesterone	 only	 contraceptives,	 intrauterine	 device,	 and	
barrier	 methods)	 or	 they	 are	 abstinent	 due	 to	 lifestyle	 choice	 or	 their	 partner	 is	 sterile	
(vasectomy).	
	
4. Standard	 contra-indications	 to	MRI:	 the	 presence	 of	 certain	metallic	 objects	 in	 the	 body	 (e.g.	
non-MRI	 compatible	 cardiac	 pacemaker,	 artificial	 joints,	 previous	 cranial	 surgery	 with	
ferromagnetic	clips,	metal	fragments	in	eye,	etc.)	and	severe	claustrophobia.	
	
5. History	of	allergic	reaction	to	any	intravenous	iron	product,	known	hypersensitivity	to	excipients,	
asthma,	eczema,	atopy,	patients	with	 immune	or	 inflammatory	conditions	(e.g.	systemic	 lupus,	
rheumatoid	 arthritis),	 any	 conditions	 associated	 with	 iron	 overload	 (e.g.	 haemochromatosis,	
chronic	 liver	 disease,	 or	 blood	 disorders	 requiring	 frequent	 blood	 transfusions),	 and	 known	
history	of	drug	allergy.	
	
6. Any	other	reason	considered	by	a	study	physician	to	make	subject	inappropriate	for	inclusion.	
	
6.3	Informed	consent	
The	chief	investigator	(CI)	will	be	responsible	to	explain	the	nature	and	purpose	of	the	study	to	the	
patient	prior	to	study	entry.	A	detailed	PIS	will	be	given	to	the	patient	and	written	informed	consent	
obtained	before	study	entry.	A	period	of	at	 least	24	hours	will	be	given	for	the	patient	to	consider	
entry	 to	 the	 study	 prior	 to	 obtaining	written	 consent	 and	 all	 efforts	will	 be	made	 to	 ensure	 that	
patients	understand	the	commitment	required	to	fulfill	the	study	requirements.	Patients	will	also	be	
made	aware	 that	participation	 is	 voluntary	and	 that	 they	can	 leave	 the	 study	at	any	 time	without	
their	standard	care	being	affected.	
	
The	 participant	 will	 be	 informed	 and	 must	 agree	 to	 their	 medical	 records	 being	 inspected	 by	
regulatory	authorities,	 research	ethics	 committee	 (REC)	 and	monitors	but	 it	will	 be	explained	 that	
their	name	will	not	be	disclosed	outside	the	study	site.			
	
Participants	will	be	given	an	alert	card	to	be	carried	at	all	times	whilst	they	are	participating	in	the	
study	containing	details	of	the	study	drug	and	contacts.	
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6.4	Potential	risks	and	benefits	
Ferumoxytol	 is	 specifically	 licensed	 for	 the	 treatment	of	 IDA	 in	patients	with	CKD.	This	 is	currently	
used	 in	 the	USA	and	Canada	but	not	 in	Europe	as	 the	company	has	withdrawn	 the	drug	 from	the	
market	purely	 for	 commercial	 reasons.	Nonetheless,	 Ferumoxytol	 is	 still	 available	 in	 the	UK	and	 is	
used	 as	 an	 unlicensed	medicine	 for	 imaging	 purposes.	 As	 with	 any	medicinal	 compound	 there	 is	
potential	for	adverse	reactions,	though	the	rates	of	these	in	clinical	trials	and	post-marketing	safety	
data	 on	 therapeutic	 use	 of	 Ferumoxytol	 are	 very	 low[23,	 32-34].	 The	 main	 concern	 has	 been	
reported	 cases	 of	 'anaphylactic'	 type	 reactions	 with	 therapeutic	 bolus	 injections	 of	 undiluted	
compound	 leading	 to	 the	 recent	 recommendations	 for	 controlled	 infusion	 of	 dilute	 Ferumoxytol.	
Rather	 than	 true	 allergy	 it	 is	 thought	 this	 is	 a	 chemotoxic	 phenomenon	 related	 to	 high	
concentrations	of	the	iron	compound	when	infused	rapidly	interacting	with	mast	cells	in	the	vascular	
wall[35].		
	
We	propose	to	use	only	a	fraction	of	the	therapeutic	dose	(approximately	a	quarter	of	the	full	dose	
for	a	70kg	adult),	much-diluted	and	slowly	 infused	to	avoid	the	risk	of	reaction.	We	will	undertake	
careful	 monitoring	 of	 patients	 during	 the	 infusions	 and	 following	 scans	 patients	 will	 undergo	 a	
period	of	close	observation.	
	
We	 have	 experience	 with	 the	 use	 of	 Ferumoxytol	 in	 a	 study	 investigating	 a	 different	 imaging	
property	 in	 greater	 than	 600	 subjects.	 No	 serious	 adverse	 events	 were	 recorded.	 We	 have	 also	
undertaken	 clinically	 indicated	 MRI	 scans	 using	 Ferumoxytol	 as	 contrast	 agent	 in	 an	 expanding	
cohort	 of	 patients	 with	 advanced	 renal	 failure	 in	 whom	 other	 imaging	 methods	 have	 proven	
problematic.	Other	centres	performing	similar	MRI	work	have	seen	no	instances	of	this	type	of	acute	
adverse	 reaction	 in	 large	 (>100)	 cohorts	 of	 patients.	 A	 recent	 survey	 (05/2015)	 of	 all	 sites	 using	
Ferumoxytol	 world-wide	 found	 that	 there	 had	 been	 about	 3,000	 imaging-related	 administrations	
without	any	serious	adverse	events	reported.	Other	investigators	have	shown	the	safety	and	utility	
of	Ferumoxytol	in	its	use	for	clinical	diagnostic	imaging	in	pediatric	patients	with	CKD[25].	
	
It	 is	 important	 to	 note	 that	 the	 above	 risks	 have	 parity	 with	 the	 other	 commonly	 administered	
intravenous	 radiological	 contrast	 media	 (whether	 iodine	 or	 gadolinium-based).	 Patients	 will	
therefore	not	be	exposed	to	disproportionate	risk.	
	
Excessive	 therapy	 with	 parenteral	 iron	 can	 lead	 to	 excess	 storage	 of	 iron	 with	 the	 possibility	 of	
iatrogenic	haemosiderosis	though	this	is	unlikely	to	occur	with	the	very	small	doses	of	iron	used	for	
imaging.	These	patients	have	regular	monitoring	of	serum	iron,	ferritin	and	transferrin	bound	iron	as	
part	of	their	routine	clinical	care.	The	results	of	the	above	tests	will	be	retrieved	and	reviewed	by	the	
study	investigators.	
	
Administration	of	Ferumoxytol	may	transiently	affect	the	diagnostic	ability	of	MRI	and	alteration	of	
MRI	 studies	may	 persist	 for	 up	 to	 3	months	 following	 infusion.	 This	 is	 the	 case	 when	 the	 higher	
therapeutic	 doses	 are	 used	 for	 iron	 supplementation.	 We	 are	 not	 expecting	 this	 effect	 with	 the	
much	lower	doses	we	are	proposing	to	use	for	imaging	purposes.	
	
In	any	case,	anticipated	MRI	studies	should	be	conducted	prior	to	the	administration	of	Ferumoxytol.	
If	MRI	 is	 required	within	3	months	after	Ferumoxytol	administration,	use	of	T1-	or	proton	density-
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weighted	MR	 pulse	 sequences	 to	minimise	 the	 Ferumoxytol	 effects	will	 be	 performed;	MRI	 using	
T2*-weighted	 pulse	 sequences	 for	 iron	 estimation	 purposes	 will	 not	 be	 performed	 earlier	 than	 4	
weeks	after	the	administration	of	Ferumoxytol.		
	
In	any	case,	Ferumoxytol	may	affect	the	appearances	only	of	certain	organs	(e.g.	liver	or	bones)	and	
this	 is	 not	different	of	what	happens	when	 intravenous	 iron	 (any	preparation)	 is	 administered	 for	
therapeutic	purposes.	The	information	of	iron	administration	as	a	contrast	agent	will	be	available	to	
the	 clinicians	 to	 avoid	 any	misinterpretation	 of	 future	MRI	 scans.	 Ferumoxytol	 does	 not	 interfere	
with	any	other	imaging	modalities	available	for	diagnosis.	There	is	no	direct	benefit	to	the	research	
participant.	They	will	have	the	knowledge	that	their	participation	is	helping	to	develop	new	methods	
to	investigate	disease	in	patients	such	as	themselves	in	future.	
	
6.5	Withdrawing	from	the	study	
The	patient	can	withdraw	or	should	be	withdrawn	under	the	following	conditions:	
	
⋅ The	patient	is	free	to	withdraw	from	the	study	at	any	point	without	giving	reason.	
⋅ The	patient	can	be	withdrawn	at	any	point	 in	time	where	the	CI	or	PI	believes	 it	 is	 in	their	
best	interest.	
⋅ The	patient	is	unable	to	adhere	to	the	study	e.g.	attending	for	MRI	scan.	
⋅ The	patient	has	an	adverse	reaction	to	Ferumoxytol.	
	
Data	 from	patients	who	withdraw	will	 be	 included	 in	 the	 final	 analysis	with	 their	 consent.	 If	 they	
prefer	they	can	choose	to	have	all	previously	collected	data	destroyed.	
	
6.6	Confidentiality	
Data	(e.g.	MRI	scans)	will	be	anonymised	with	only	a	study	code	identifying	data	for	the	purposes	of	
research	analysis	on	university	network	storage.	Each	patient	will	have	a	clinical	research	file	(CRF)	
created	with	the	link	to	this	held	in	a	locked	office	in	BHF	Cardiovascular	Research	Building.	
	
All	 referrals	 for	 imaging	are	made	through	password-protected	software.	The	referrals	can	only	be	
read	 by	 password-protected	 software.	 The	 imaging	 data	 obtained	 from	 the	 study	 is	 recorded	 on	
computers	 within	 a	 building	 with	 secure	 access.	 These	 computers,	 and	 the	 imaging	 software	 on	
them,	 are	 also	 password-protected.	 Images	 and	 reports	 subsequently	 transferred	 to	 the	 Scottish	
National	PACS	are	also	only	accessible	via	password-protected	software	for	those	involved	in	patient	
care.	
	
7.	Study	Outcomes	
	
7.1	Primary	outcome	
The	primary	outcome	 is	comparison	of	FeMRA	with	standard	 imaging	techniques	 in	assessment	of	
vascular	 anatomy.	 Multiple	 cross	 sections	 of	 various	 vascular	 beds	 obtained	 with	 currently	 used	
imaging	 techniques	 will	 be	 compared	 with	 matched	 sections	 obtained	 with	 FeMRA	 in	 a	 blinded	
fashion	 (Table	 2).	 The	 emphasis	 is	 generally	 on	 imaging	 quality	 and	 diagnostic	 accuracy	 on	
identification	of	clinically	significant	anatomic	characteristics	or	lesions	(Table	3).	
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7.2	Secondary	outcomes	
	
1. Anatomical	 predictors	 of	 ultrasound-based	 anatomical	 fistula	maturation	 at	 6	weeks	 after	
creation.	
Criteria	of	ultrasound-based	fistula	maturation	include:	
-	 AVF	lumen	diameter	>4mm	and		
-	 AVF	blood	flow	>500mL/min	
	
2. Fistula	 or	 graft	 complications:	 stenosis,	 thrombosis,	 hand	 ischaemia,	 aneurysm	 or	
pseudoaneurysm,	infiltration,	fistula	bleeding,	and	infection.	
	
3. Fistula	or	graft	procedures:	surgical	 revision,	angioplasty,	stent	placement,	 thrombolysis	or	
thrombectomy,	 ligation	of	 accessory	 veins,	 superficialisation	of	 vein,	 transposition	of	 vein,	
central	venous	catheter	use,	and	placement	of	new	arteriovenous	access.	
 
4. Utility	 of	 FeMRA	 in	 assessment	 of	 cardiac	 anatomy,	 function	 and	microcirculation	 kinetics	
before	listing	for	kidney	transplantation.	
 
5. Association	between	cardiac	function	and	fistula	(or	graft)	outcomes	assessed	by	FeMRA.	
	
6. Effect	of	successful	fistula	(or	graft)	creation	on	cardiac	function	assessed	by	FeMRA.	
	
7. Utility	 of	 FeMRA	 to	 characterise	 changes	 in	 cardiac	 microcirculation	 kinetics	 following	
formation	of	a	dialysis	fistula	or	graft	(ischaemic	pre-conditioning	hypothesis).	
	
8. Utility	of	FeMRA	in	assessment	of	cardiac	morphology,	coronary	blood	supply,	microvascular	
perfusion,	and	tissue	characterisation	(sub-study).	
	
	
8.		Data	collection	&	management	
	
8.1	Data	collection	
The	 data	 will	 be	 collected	 by	 the	 research	 fellow	 (CI)	 on	 paper	 with	 subsequent	 transcription	 to	
electronic	 form.	The	medical	notes	will	 act	as	 source	data	 for	demographics,	past	medical	history,	
medications	and	blood	results.	
	
8.2	Data	storage	
Anonymised	data	will	be	stored	on	University	of	Glasgow	computers	and	hardware	encrypted	hard	
drives,	 accessed	 by	 members	 of	 the	 primary	 research	 team	 only.	 Each	 patient	 will	 have	 a	 CRF	
created	with	the	link	to	this	held	in	a	locked	office	in	BHF	Cardiovascular	Research	Building.	Clinical	
imaging	data	will	be	stored	on	the	National	PACS	and	will	remain	stored	on	this	password-protected	
system	 for	 as	 long	 as	 imaging	 on	 any	 patient	 in	 Scotland	 is	 stored.	 Access	 is	 available	 to	 any	
healthcare	professional	with	credentials	that	allow	access	to	PACS	within	the	ethical	boundaries	of	
Good	Medical	Practice	as	defined	by	the	General	Medical	Council.	
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The	CI	will	have	control	of	and	act	as	the	custodian	for	the	data	generated	by	the	study.	
	
	
9.	Statistical	Considerations	
	
The	 general	 analytical	 approach	 will	 be	 to	 estimate	 accuracy	 (95%	 CI),	 sensitivity	 (95%	 CI)	 and	
specificity	(95%	CI)	of	FeMRA	and	standard	imaging	techniques.	 In	addition,	Cohen’s	κ	with	95%	CI	
will	be	computed	 to	compare	arterial	 sections	 that	 can	be	assessed	with	both	 imaging	 techniques	
(i.e.	 FeMRA	 vs.	 CTA/US)	 and	 quantify	 the	 agreement	 between	 the	 FeMRA	 and	 standard	 imaging	
findings.	A	value	of	κ>0.7	indicates	a	high	level	of	agreement.	For	venous	sections	that	can	only	be	
assessed	with	FeMRA	(i.e.	central	veins	in	thorax,	veins	in	lower	limbs)	percentages	and	confidence	
intervals	will	be	used.	
	
Because	multiple	 image	 locations	 from	 each	 patient	will	 be	 used	 for	 the	 statistical	 evaluation	 (at	
least	20	vascular	cross	sections	 from	each	scan),	 the	 interdependence	of	each	 location	 for	a	given	
patient	examination	will	be	assessed	by	use	of	a	κ	 statistic.	A	value	of	κ<0.4	 indicates	weak	or	no	
interdependence.	
	
We	 initially	 aimed	 to	 recruit	 30	 patients	 in	 each	 group	 (60	 patients	 in	 total).	 If	 we	 assume	 that	
FeMRA	will	identify	10%	more	clinically	significant	vascular	anatomic	characteristics	compared	with	
CTA/US,	then	one	would	need	to	study	180	vascular	sections	in	total	to	show	a	significant	difference	
between	tests	using	chi-squared	test,	assuming	power	of	80%	and	probability	of	type	1	error	of	5%.	
	
We	reviewed	the	data	from	the	first	17	patients	to	ensure	our	sample	size	of	60	patients	would	be	
sufficient	 to	confirm	our	 study	hypothesis.	 From	these	patients,	8	were	 in	group	A,	and	9	were	 in	
group	B.				
	
A	 total	 of	 340	 vascular	 sections	 were	 assessed	 by	 one	 observer.	 Image	 quality	 on	 steady-state	
acquisitions	was	scored	as	grade	4	in	260	of	340	(76.5%,	90%	confidence	interval	72-79%)	and	grade	
3	in	80	of	340	(23.5%)	vascular	sections	(at	least	diagnostic	quality)	when	assessing	the	arterial	and	
venous	vasculature	with	FeMRA.	There	were	no	arterial	anatomic	characteristics	or	lesions	of	clinical	
significance	that	were	identified	on	CTA	and	not	on	FeMRA	(and	vice	versa)	 in	group	A.	 In	group	B	
FeMRA	 identified	 2%	more	 significant	 arterial	 stenoses	 compared	 with	 US.	 There	 was	 very	 good	
agreement	on	assessment	of	 image	quality	 in	arteries	between	FeMRA	and	CTA	 (kappa=0.85)	and	
moderate	 agreement	 between	 FeMRA	 and	 US	 (kappa=0.65).	 On	 assessment	 of	 the	 venous	
vasculature,	5%	more	anatomical	 characteristics	of	 significance	 (i.e.	 stenosis,	occlusion,	 aneurysm,	
presence	 of	 thrombus)	 were	 identified	 with	 FeMRA	 compared	 with	 standard	 imaging	 methods	
(which	cannot	assess	venous	vasculature).		
	
Based	on	these	preliminary	findings,	we	aim	to	increase	the	number	of	participants	(40	in	group	A,	
60	in	group	B)	to	ensure	adequate	power	to	reject	a	false	null	hypothesis,	as	FeMRA	can	identify	3-
5%	more	clinically	significant	vascular	anatomic	characteristics	compared	with	CTA/US	(rather	than	
10%	that	was	initially	assumed).		
	
	28	
	
To	evaluate	associations	between	anatomical	predictor	variables	and	outcomes,	multiple	linear	and	
logistic	mixed-effects	regression	models	will	be	used.	Associations	of	fistula	and	graft	outcomes	with	
predictors	 will	 be	 treated	 as	 uniform	 across	 all	 anatomical	 configurations	 unless	 there	 is	 strong	
statistical	 or	 biological	 evidence	 to	 suggest	 otherwise.	 Based	 on	 data	 from	 a	 retrospective	 study	
performed	in	our	centre[36]	we	assume	a	fistula	failure	rate	of	30%	(40%	for	patients	on	dialysis	and	
20%	for	pre-dialysis	patients).	
	
	
10.	Study	conduct	responsibilities	
	
10.1	Protocol	amendments	
Any	changes	 to	 the	 final	approved	protocol	will	 require	an	amendment.	The	CI	will	 liaise	with	 the	
sponsor	to	determine	whether	an	amendment	is	substantial	or	non-substantial.	Amendments	to	the	
protocol	will	 be	 submitted	 in	writing	 to	 the	 Sponsor	 for	 approval	 prior	 to	 being	 submitted	 to	 the	
appropriate	REC,	Regulatory	Authority	and	local	NHS	Research	and	Development	(R&D)	for	approval.	
All	 approvals	 will	 be	 in	 place	 prior	 to	 participants	 being	 enrolled	 into	 an	 amended	 protocol.	 All	
amended	versions	of	the	protocol	will	be	signed	by	the	CI	and	the	sponsor	representative.	
	
10.2	Protocol	violations	and	deviations	
The	CI	will	 not	 implement	 any	 deviation	 from	 the	 protocol	without	 agreement	 from	 the	 Sponsor,	
appropriate	REC,	Regulatory	Authority	and	without	local	NHS	R&D	approval,	except	where	necessary	
to	eliminate	an	immediate	hazard	to	trial	participants.	
	
In	 the	 event	 that	 any	 study	 investigator	 needs	 to	 deviate	 from	 the	 protocol,	 the	 nature	 of	 and	
reasons	for	the	deviation	will	be	recorded	 in	the	CRF,	documented	 in	a	Breaches	&	Deviations	Log	
and	 submitted	 to	 the	Sponsor.	 If	 this	necessitates	a	 subsequent	protocol	 amendment,	 this	will	 be	
submitted	 to	 the	Sponsor	 for	approval	and	then	to	 the	appropriate	REC,	Regulatory	Authority	and	
local	NHS	R&D	for	review	and	approval	as	appropriate.	
	
10.3	Study	record	retention	
As	the	data	from	this	study	does	not	form	part	of	an	application	for	a	Marketing	Authorisation	all	
study	documentation,	including	medical	case	notes,	will	be	kept	for	at	least	5	years.	
	
10.4	Study	auditing	
The	study	will	be	subject	to	auditing	by	the	sponsor,	depending	on	the	sponsor’s	risk	assessment	and	
audit	 schedule.	 The	 CI	 will	 permit	 trial	 related	 monitoring,	 audits,	 REC	 review,	 and	 regulatory	
inspections.	 In	 the	 event	 of	 an	 audit,	 the	 CI	 agrees	 to	 allow	 the	 Sponsor,	 representatives	 of	 the	
Sponsor	or	regulatory	authorities	direct	access	to	all	study	records	and	source	documentation.	
	
10.5	End	of	study	
The	study	will	conclude	after	the	last	participant’s	last	visit.	
	
The	CI	has	the	right	at	any	time	to	terminate	the	study	for	clinical	or	administrative	reasons.		
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The	end	of	the	study	will	be	reported	to	the	Sponsor,	REC	and	Regulatory	Authority	within	90	days,	
or	15	days	if	the	study	is	terminated	prematurely.	The	CI	will	ensure	that	any	appropriate	follow	up	
is	arranged	for	all	participants.	
	
A	summary	report	of	the	study	will	be	provided	to	the	Sponsor,	REC	and	Regulatory	Authority	within	
1	year	of	the	end	of	the	study.	
	
10.6	Archive	
On	completion	of	the	study,	the	protocol,	data,	and	report	will	be	archived	in	the	sponsor	archives.	
Data	will	be	stored	anonymously	and	for	a	period	of	5	years.	
	
	
11.	Reports,	Dissemination	of	findings	
11.1	Authorship	policy	
Ownership	 of	 the	 data	 arising	 from	 this	 study	 resides	 with	 the	 study	 team	 and	 their	 respective	
employers.	On	completion	of	the	study,	the	study	data	will	be	analysed	and	tabulated,	and	a	clinical	
study	report	will	be	prepared.	
	
11.2	Reports	
Annual	reports	will	be	submitted	to	the	approving	ethical	committee	and	the	sponsor.	A	final	report	
will	also	be	issued	to	these	groups.	No	patient	identifiable	data	will	be	included.	
	
11.3	Publication	
The	 clinical	 study	 report	 will	 be	 used	 for	 publication	 and	 presentation	 at	 scientific	 meetings.	
Investigators	 have	 the	 right	 to	 publish	 orally	 or	 in	writing	 the	 results	 of	 the	 study.	 Summaries	 of	
results	 will	 also	 be	 made	 available	 to	 Investigators	 for	 dissemination	 within	 their	 clinics	 (where	
appropriate	and	according	to	their	discretion).	
	
Patients	will	be	provided	with	a	summary	in	lay	language	of	the	results	of	the	study	in	the	form	of	a	
simple	letter	including	thanks/acknowledgment	of	participation.	
	
11.4	Peer	review	
Peer	 review	 of	 the	 protocol	 will	 occur	 via	 the	 Sponsorship	 Committee	 and	 of	 the	 resulting	
publication	by	the	referees	of	the	journal	to	which	the	paper	(and	its	protocol)	will	be	submitted.	
	
This	 study	 will	 be	 submitted	 for	 further	 funding	 and	 peer	 review	 to	 the	 NHS	 GG&C	 Research	
Endowment	Fund	Allocation	and	British	Renal	Society.	
	
	
12.	Pharmacovigilance	
12.1	Definition	of	adverse	events 
The	following	definitions	will	be	used.			
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• Adverse	Reaction	 (AR):	 any	untoward	and	unintended	response	 in	a	 subject	 to	a	 research	
product	which	is	related	to	any	dose	administered	to	that	subject.	
• Serious	Adverse	Event	Reporting:	a	Serious	Adverse	Event	(SAE)	is	defined	as	an	untoward	
occurrence	 that:	 (a)	 results	 in	 death;	 (b)	 is	 life-threatening;	 (c)	 requires	 hospitalisation	 or	
prolongation	 of	 existing	 hospitalisation;	 (d)	 results	 in	 persistent	 or	 significant	 disability	 or	
incapacity;	(e)	consists	of	a	congenital	anomaly	or	birth	defect;	or	(f)	is	otherwise	considered	
medically	significant	by	the	investigator.	
	
12.2	Adverse	event	recording	
AEs	must	be	recorded,	assessed,	reported,	analysed	and	managed	in	accordance	with	the	Research	
Governance	 Framework	 for	 Health	 and	 Community	 Care	 and	 the	 study	 protocol.	 All	 AEs	must	 be	
assessed	for	seriousness.			
	
12.3	Serious	adverse	events	and	serious	adverse	reactions	recording	and	reporting	
Where	 an	 SAE	 requires	 recording,	 full	 details	 should	 be	 documented	 including	 the	 nature	 of	 the	
event,	start	and	stop	dates,	severity,	relationship	to	research	product	and/or	procedures.	Outcome	
will	 be	 recorded	 in	 the	 patient’s	 CRF	 and	 medical	 notes.	 These	 events	 will	 be	 monitored	 and	
followed	 up	 until	 satisfactory	 resolution	 and	 stabilisation.	 SAEs	must	 be	 assessed	 to	 determine	 if	
related	to	the	research	procedures	(includes	administration	of	research	products)	and	expectedness.				
• Related:	that	is,	it	resulted	from	administration	of	research	products	or	any	of	the	research	
procedures.	
• Expectedness	 for	 SAR:	 that	 is,	 the	 expectedness	 of	 an	 adverse	 reaction	 to	 administered	
research	products	is	assessed	against	the	prescribing	information	available	for	Ferumoxytol	
injection.	
• Expectedness	for	SAEs:	is	assessed	against	the	research	procedure	events	listed	in	the	study	
protocol	as	an	expected	occurrence.			
	
All	 SAEs	 and	 SARs	must	 be	 reported	 to	 the	 pharmacovigilance	 (PV)	 office	 immediately	 (within	 24	
hours)	using	the	generic	non-clinical	trial	of	an	investigational	medicinal	product	(CTIMP)	SAE	form	
which	is	available	from	http://www.glasgowctu.org/data/SAE_non-CTIMP.pdf.	The	SAE	form	should	
be	completed	and	signed	by	appropriately	delegated	staff.	The	form	should	be	faxed	or	e-mailed	to	
the	PV	Office	(pharmacovig@glasgowctu.org)	and	a	copy	placed	in	the	Study	Site	File.		If	necessary	a	
verbal	report	can	be	given	by	contacting	the	PV	Office	on	0141	330	4744.	This	must	be	followed	up	
as	soon	as	possible	with	a	signed	written	(or	electronic)	report.	
	
If	all	of	the	required	information	is	not	available	at	the	time	of	initial	reporting,	the	CI	(or	designee)	
must	 ensure	 that	 any	missing	 information	 is	 forwarded	 to	 the	 PV	Office	 as	 soon	 as	 this	 becomes	
available.	The	report	should	indicate	that	this	 information	is	follow	up	information	for	a	previously	
reported	event.	
	
12.4	Reporting	of	SARs	and	SAEs	to	the	Ethics	Committee	
Reports	 of	 SARS	 and	 SAEs	 should	 be	 submitted	 within	 15	 days	 of	 the	 CI	 becoming	 aware	 of	 the	
event,	 using	 the	 ‘report	 of	 serious	 adverse	 event	 form’	 for	 non-CTIMPs	 published	 on	 the	 Health	
Research	 Authority	 web	 site:	 http://www.hra.nhs.uk/documents/2015/02/safety-report-form-non-
ctimp.docx.	The	form	should	be	completed	in	typescript	and	signed	by	the	CI.			
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12.5	Annual	progress	reports	
The	CI	must	also	provide	an	annual	progress	report	to	the	REC.	A	report	on	the	safety	of	participants	
will	be	included	as	part	of	this	report.		
	
12.6	Reporting	to	the	Medicines	and	Healthcare	Products	Regulatory	Agency	(MHRA)	
Whilst	there	is	no	statutory	requirement	to	report	to	the	MHRA,	adverse	reactions	to	Ferumoxytol	
may	be	reported	to	the	MHRA	YellowCard	Scheme	(www.mhra.gov.uk/yellowcard).	
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Table	1.	Infusion	protocol	
Weight	(kg)	 Ferumoxytol	
Dose	(mg)	
Volume	of	
Ferumoxytol	injection	
required	to	prepare	
infusion	(ml)	
(1ml	of	solution	contains	
30mg	iron	as	ferumoxytol)	
Volume	of	0.9%	
sodium	chloride	
required	to	prepare	
final	infusion	(ml)	
Final	prepared	
Ferumoxytol	
infusion	volume	
(ml)	
40-45	 135	 4.5	 18.0	 22.5	
46-50	 150	 5.0	 20.0	 25.0	
51-55	 165	 5.5	 22.0	 27.5	
56-60	 180	 6.0	 24.0	 30.0	
61-65	 195	 6.5	 26.0	 32.5	
66-70	 210	 7.0	 28.0	 35.0	
71-75	 225	 7.5	 30.0	 37.5	
76-80	 240	 8.0	 32.0	 40.0	
81-85	 255	 8.5	 34.0	 42.5	
86-90	 270	 9.0	 36.0	 45.0	
91-95	 285	 9.5	 38.0	 47.5	
96-100	 300	 10.0	 40.0	 50.0	
≥100	 300	 10.0	 40.0	 50.0	
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Table	2.	Vessel	locations	to	be	assessed	
	
Pre-transplant	assessment	
	
Vascular	mapping	 Fistula	(or	graft)	surveillance	
Arterial	vasculature	 Vein	 mapping	 (peripheral	
veins)	
Inflow	 artery	 proximal	 to	 the	
fistula	or	graft	
Abdominal	aorta	 Cephalic	 vein	 at	 the	 proximal	
upper	arm	
Inflow	 artery	 distal	 to	 the	
fistula	or	graft	
Coeliac	artery	 Cephalic	 vein	 at	 the	mid-upper	
arm	
Anastomotic	 sites	 (fistula	 has	
one	site,	graft	has	two	sites)	
Superior	mesenteric	artery	 Cephalic	 vein	 at	 the	 distal	
upper	arm	
Puncture	sites	
Inferior	mesenteric	artery	 Cephalic	vein	at	the	antecubital	
fossa	
Outflow	 vein	 proximal	 to	 the	
fistula	or	graft	
Renal	arteries	 Cephalic	 vein	 at	 the	 proximal	
forearm	
Outflow	 vein	 middle	 to	 the	
fistula	or	graft	
Common	iliac	arteries	 Cephalic	 vein	 at	 the	 mid-
forearm	
Outflow	 vein	 distal	 to	 the	
fistula	or	graft	
External	iliac	arteries	 Cephalic	 vein	 at	 the	 distal	
forearm	
External	jugular	veins	
Internal	iliac	arteries	 Cephalic	vein	at	the	wrist	 Subclavian	veins	
Venous	vasculature	 Basilic	 vein	 at	 the	 proximal	
upper	arm	
Axillary	veins	
Inferior	vena	cava	
	
Basilic	 vein	 at	 the	 mid-upper	
arm	
Brachiocephalic	veins	
Renal	veins	
	
Basilic	 vein	 at	 the	 distal	 upper	
arm	
Superior	vena	cava	
Common	iliac	veins	
	
Basilic	 vein	 at	 the	 antecubital	
fossa	
	
External	iliac	veins	 Vein	mapping	(central	veins)	
	
	
Internal	iliac	veins	 External	jugular	veins	 	
Common	femoral	veins	 Subclavian	veins	 	
Superficial	femoral	veins	 Axillary	veins	 	
Profunda	femoral	veins	 Brachiocephalic	veins	 	
Greater	saphenous	veins	 Superior	vena	cava	 	
Popliteal	veins	 Arterial	mapping	
	
	
	 Brachial	 artery	 at	 the	
antecubital	fossa	
	
	 Radial	artery	at	the	wrist	
	
	
	 Level	 of	 brachial	 artery	
bifurcation	 relative	 to	 the	
antecubital	fossa	
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Table	3.	Anatomical	characteristics	or	lesions	to	be	assessed	
	
Artery	diameter	
Vein	diameter	
Stenosis	
Occlusion	
Vessel	irregularity	
Luminal	narrowing	
Wall	thickening	
Calcification	
Aneurysm/pseudoaneurysm	
Presence	of	thrombus	
	
Fistula	(or	graft)	specific	
Vein	depth	from	skin	surface	
Fistula	(or	graft)	diameter	
Fistula	(or	graft)	stenosis	
Fistula	(or	graft)	thrombosis	
Inflow	stenosis	
Outflow	stenosis	
Length	of	straight	segment	for	cannulation	
Blood	flow	rate	
	
